Skip to main content

Super navigation EU

  • Newsroom
    • The Latest
    • Press releases
    • argenx Stories
    • Downloadable assets
  • Investors
A
A

Main navigation additional

  • Home
  • Contact us
  • Home
  • Patients
    • Our commitment
    • Disease areas
    • MyRealWorld MG
    • Patient access
  • Innovation
    • Science of collaboration
    • IIP
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Careers
    • Dare to do more
    • Benefits
    • Employee stories
    • Find your job
  • About
    • One Team
    • Values
    • Management Team
    • Board of Directors
    • Grants
    • Ethics and Responsibility
    • Contact us
Home

Secondary navigation additional

  • Contact

Secondary/mobile navigation (UK)

  • Home
  • Patients
    • Our commitment
    • Disease areas
    • MyRealWorld MG
    • Patient access
  • Innovation
    • Science of collaboration
    • IIP
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Careers
    • Dare to do more
    • Benefits
    • Employee stories
    • Find your job
  • About
    • One Team
    • Values
    • Management Team
    • Board of Directors
    • Grants
    • Ethics and Responsibility
    • Contact us

Innovation

Breadcrumb

  1. Home
  2. Innovation
The Science of Collaboration

We bring our antibody engineering expertise to pioneering researchers with the intent to advance immunology breakthroughs into differentiated medicines for patients.

Through collaboration, we have a common purpose and can accelerate discovery processes to bring solutions to patients who need them.

We know that together we are better.

Immunology Innovation Program (IIP)

The Immunology Innovation Program (IIP) is a core business strategy of argenx connecting the specialized insight into disease and target biology of our external scientific and academic collaborators with our unparalleled experience as antibody engineers.

Co-creation has led to a deep pipeline of highly differentiated product candidates.

Through the IIP, we hope to together transcend breakthrough research and publications to our ultimate and unifying mission of creating new potential treatment options for patients.

 

An Innovation Ecosystem

"Stepping into these strategic, academic, industry collaborations. This is a wonderful ecosystem that we are creating, by bringing that expertise together.”

Prof. Bart Lambrecht

Bringing expertise together

 

 

Academic Collaborators

Image
Bern University
Bern University
Image
Columbia University
Columbia University
Image
Institut de Duve
Institut de Duve
Image
Leiden University
Leiden University
Image
Ludwig Cancer Research
Ludwig Cancer Research
Image
National Jewish Health
National Jewish Health
Image
Université Catholique de Louvain
Université Catholique de Louvain
Image
Unito
Turin University
Image
University Of Pennsylvania
University Of Pennsylvania
Image
NYU School of Medicine
NYU School of Medicine
Image
UT Southwestern
UT Southwestern
Image
Flemish Institute for Biotechnology
Flemish Institute for Biotechnology
Image
Utrecht University
Utrecht University

Antibody Engineering

Innovation and co-creation are at the core of our strategy. We integrate our unique antibody engineering capabilities with the deep disease and target biology expertise of our collaborators. By innovating at the discovery level, we have built a broad pipeline of differentiated potential immunology solutions to offer patients.

We innovate at both the variable region or V region (where antigens and foreign proteins are recognized) and the constant region or Fc region (where antibodies modulate other cells in the immune system):

Antibody

V region
FC region

Technology Role

Suite of Technologies

Unlock novel and complex targets
SIMPLE Antibody™ Platform

SIMPLE Antibody™ is argenx's proprietary platform designed to source V regions from the immune system of "outbred" llamas.

Modulate immune response

Three Fc engineering technologies (NHANCE®, ABDEG™ and POTELLIGENT®) are intended to expand the therapeutic index of argenx antibodies.

Unique suite of technologies enables development of differentiated product candidates against novel targets

Partnering opportunities

Deep relationships power the core of our innovation ecosystem, it is a system of co-creation.

The Immunology Innovation Program is based on mutual respect for the expertise that each partner brings. Our research collaborators bring unique knowledge of disease biology or a disease pathway. argenx can offer antibody engineering capabilities and a path to turn an immunology breakthrough into a clinical development candidate.

We together with our partners have the potential to create differentiated medicines for patients.

For more information on partnering opportunities, please contact [email protected]

argenx respects your privacy
Personal information is never kept longer than necessary. Personal data is not provided to third parties without permission or used for marketing purposes.

Home
  • Home
  • Contact us

Footer navigation (UK)

  • Home
  • Patients
    • Our commitment
    • Disease areas
    • MyRealWorld MG
    • Patient access
  • Innovation
    • Science of collaboration
    • IIP
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Careers
    • Dare to do more
    • Benefits
    • Employee stories
    • Find your job
  • About
    • One Team
    • Values
    • Management Team
    • Board of Directors
    • Grants
    • Ethics and Responsibility
    • Contact us
2023 © argenx
Disclaimer
Privacy policy